SecBot SecBot
SECBOTREPLAY Home › Report › TBPH

TBPH · Theravance Biopharma reported Q1 2026 revenue of $17.7M (+15% YoY),…

Theravance Biopharma, Inc. · 8-K filed May 7, 2026 at 08:36 ET

At the news

MIXEDIMPACT 5/10

8-K filed May 7, 2026 at 08:36 ET

Theravance Biopharma reported Q1 2026 revenue of $17.7M (+15% YoY), slightly above the $17.4M consensus, but GAAP EPS of -$0.10 missed the Street estimate of -$0.05. Net loss improved to -$4.9M from -$13.6M a year ago, and non-GAAP net income turned positive at $0.6M. The company reaffirmed its restructuring and cost-cutting targets, while the strategic review for a potential sale continues.

  • Total revenue $17.7M, up 15% YoY from $15.4M, entirely from Viatris collaboration
  • GAAP net loss per share -$0.10 vs. consensus -$0.05 (100% miss)
  • Net loss narrowed to $4.9M from $13.6M in Q1 2025
  • Non-GAAP net income from operations was $0.6M vs. -$8.6M last year

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access